BOEHRINGER Ingelheim says it’s
now “extremely confident” that
its novel anticoagulant Pradaxa
(dabigatran) will be PBS listed on 01
Sep for patients with non-valvular
atrial fibrillation and at least one
additional risk factor for stroke.
The company said it’s now
completed all the paperwork and
processes to enable the PBS listing,
and thanked doctors who cared for
around 25,000 AF patients during
the past two years as part of the
product familiarisation program.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jul 13
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.